resistance in other Plasmodium species yet. Lack of artemisinin efficacy leaves the ACT partner drug unprotected. Inevitably partner drug resistance (mefloquine, piperaquine) has now followed and recent therapeutic efficacy studies in Thailand and Cambodia show an alarming rise in ACT treatment failure rates [10e13] . This should be set against a steady reduction in the incidence of malaria in the region. Thus while the risk of treatment failure has risen, the risk of acquiring malaria has fallen.
Artemisinin resistance can be assessed by various methods including measurement of the parasite clearance half-life, a cruder surrogate e the proportion of cases still parasite positive by microscopy at day 3, in-vitro tests assessing ring stage susceptibility, and sequencing of Pfkelch13 (K13 mutations in the "propeller region" of the gene are associated strongly with resistance) [3, 14] . ACT treatment efficacy is assessed using standard therapeutic efficacy testing of ACTs with 42-day follow up [3] . The updated global distribution of artemisinin resistance can be followed using the K13 Molecular Surveyor, an interactive map provided by the Worldwide Antimalarial Resistance Network (Fig. 1) , that shows the current K13 mutation prevalence (http://www.wwarn.org/molecularsurveyor-k13). Fig. 1 . A map of prevalence of K13 mutations from K13 Molecular Surveyor as accessed on 16 November 2016. K13 mutations have been reported from all malaria endemic areas [9] . Some are not associated with artemisinin resistance, and apart from the Greater Mekong subregion of Southeast Asia, there is no evidence that they are being selected elsewhere [15] . This suggests that other genetic changes (collectively termed the "genetic backbone") contribute to resistance. The great concern is that this genetic backbone and associated K13 mutations will spread to India and Africa. These resistant parasites have already been shown capable of infecting the main African vector Anopheles gambiae [16] . Travel between Asia and Africa is very frequent so the spread potential appears high. Recent studies suggest the emergence of a few presumably fitter parasite lineages which have outcompeted the other artemisinin-resistant parasites and spread over long distances. In doing so they have acquired partner drug resistance. The same evolutionary pattern occurred before when chloroquine and sulfadoxine-pyrimethamine resistance spread from the Greater Mekong subregion to Africa [1, 2] . This has led to calls for regional elimination of P. falciparum malaria before it spreads to infect the rest of the tropical world [17] .
Southeast Asia is not only the epicentre of antimalarial drug resistance. It is one of the most popular travel destinations. Globally, the number of international travelers to the region continues to grow. International tourist arrivals reached 104.3 million in 2015. Thailand, the region's top destination, welcomed 5 million more international tourists in 2015 than it did in 2014. Myanmar, Laos, the Philippines and Indonesia also enjoyed a quick expansion of traveler arrivals. Tourism in Cambodia is slowly yet steadily growing [18] . Visa exemption among ASEAN members also facilitates population movement and, as an unintended by-product, disease movement.
What does all this mean for the traveler? For the vast majority of the malaria-affected world the recommended malaria preventive measures are unaffected. As ever, personal protection from mosquito bites is paramount. In those few forested places where intrepid travelers can acquire malaria in the Greater Mekong subregion, the prophylactic efficacy of atovaquone-proguanil, doxycycline and primaquine should be unaffected by worsening resistance to the ACTs. However, mefloquine will not be as effective as it was previously along the Thailand-Myanmar border. In the treatment of symptomatic falciparum malaria, therapeutic responses to ACTs are slower and failure rates higher, although recent data for artemether-lumefantrine in Thailand and Cambodia are lacking, and elsewhere including most of Myanmar artemetherlumefantrine works well. P. vivax remains generally well behaved despite increasing chloroquine resistance. In the absence of further information severe falciparum malaria from areas of known artemisinin resistance should be treated with both artesunate and quinine in full doses. Events are changing rapidly so recommendations for both chemoprophylaxis and treatment should be reviewed frequently.
